This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
AMY2A / Pancreatic alpha-amylase · IHC design guide
Design Immunohistochemistry for AMY2A
Plan AMY2A IHC in paraffin sections using pancreatic exocrine cells as the expected positive population (HPA tissue IHC). This guide covers fixation, staining controls, and interpretation of cytoplasmic signal in the context of a secreted protein (HPA tissue IHC; UniProt).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
AMY2A Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Cytoplasmic staining observed in pancreatic exocrine cells (HPA tissue IHC) | |
| Staining pattern | Selective cytoplasmic staining in pancreatic exocrine cells (HPA tissue IHC) | |
| Antigen retrieval | Citrate pH 6.0 HIER, 95–98 °C, 20 min (rule: cytoplasmic / membrane antigen) | |
| Positive control | Pancreas | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Matched tissue-IHC evidence does not establish the fixation claim. Validate the specimen-specific method before use. (selected-SKU IHC image A06771) | |
| Caveat | Secreted protein may extend beyond its producing cells (UniProt) | |
| Regulation | Regulation not annotated (UniProt) | |
| Isoform / epitope | 2 isoforms; signal peptide is cleaved; epitope unknown (UniProt) |
Section 1
Recommended AMY2A IHC & IF Protocols
The catalog antibody IHC-P protocol (datasheet) is paired with a published AMY2A brain-section IHC protocol (PMC8028266).
| Sample | Paraffin-embedded human liver injury tissue; fixative not specified (datasheet A06771) |
| Fixation | Image fixative and duration unreported (datasheet A06771); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat-induced epitope retrieval in citrate buffer, pH 6.0, 20 min at 95–98 °C (standard rule: cytoplasmic / membrane antigen) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% normal serum of the secondary host, 30 min, room temperature (standard) |
| Primary antibody | Rabbit anti-AMY2A, 1:50-1:200 (datasheet A06771) |
| Primary incubation | Overnight at 4 °C (standard) |
| Detection | HRP-polymer secondary, DAB chromogen 5–10 min (standard) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | AMY2A-positive staining in exocrine glandular cells of pancreas (HPA tissue IHC: High). HPA tissue profile: Selective cytoplasmic expression in pancreatic exocrine glandular cells. No signal in the no-primary control. |
💡Decision noteFor paraffin sections, start with citrate pH 6.0 retrieval at 95–98 °C for 20 min (page retrieval rule); the published excerpt does not specify retrieval (PMC8028266).
Section 2
What Is the Expected AMY2A Staining Pattern?
AMY2A should give high cytoplasmic staining in pancreatic exocrine glandular cells (HPA tissue IHC: Enhanced reliability). It is a secreted protein with no transmembrane segment, so its observed cellular staining need not imply permanent residence in the cytoplasm (UniProt P04746: secreted; no transmembrane segment). HPA cautions that the tissue pattern includes proteins from more than one gene and that protein and RNA locations may differ for a secreted protein (HPA tissue IHC).
| Strong cytoplasmic signal in pancreatic exocrine glandular cells, with tissue structure visible around them. | This matches the reference IHC pattern: selective cytoplasmic expression at a high level in those cells (HPA tissue IHC). Score the stained cells and compartment together; intensity alone does not identify AMY2A because HPA cautions that the pattern includes proteins from more than one gene (HPA tissue IHC). |
| Predominantly nuclear or sharply membrane-restricted signal in pancreatic exocrine glandular cells. | That differs from HPA's observed cytoplasmic IHC pattern (HPA tissue IHC) and does not follow from the secreted, non-transmembrane annotation (UniProt P04746 topology). Treat it as a possible staining artefact and review morphology and controls before assigning a target location (general IHC practice). |
| Clear signal in an unexpected cell type, especially a cell type reported as not detected in the supplied HPA tissue profile. | For example, HPA reports adipocytes in adipose tissue as not detected (HPA tissue IHC). Such staining warrants a specificity check; antibody cross-reactivity or endogenous detection activity are possible explanations (general IHC practice). HPA's multi-gene targeting caution also limits assignment of a positive cell to AMY2A alone (HPA tissue IHC). |
| Diffuse colour across cells and surrounding tissue, without a discernible exocrine cytoplasmic pattern. | This is not the selective pancreatic exocrine pattern used as the reference (HPA tissue IHC). Assess background with an appropriate negative control and compare stained and unstained tissue areas before scoring cells as positive (general IHC practice). Secreted protein can have a tissue distribution different from its RNA source, so location alone cannot establish its source (HPA tissue IHC). |
| No signal in a pancreatic section containing identifiable exocrine glandular cells. | The section has failed to show the expected high positive cell population (HPA tissue IHC). Confirm that the relevant cells are present, then review antibody and chromogenic detection controls, retrieval, and staining conditions (general IHC practice). One negative run cannot establish that AMY2A is absent from the sample. |
💡Expected AMY2A appearanceCall the IHC result positive when pancreatic exocrine glandular cells show high cytoplasmic staining (HPA tissue IHC); nuclear, sharply membrane-restricted, or indiscriminate diffuse colour is a suspect pattern (HPA tissue IHC; general IHC practice).
| Tissue and cell selection | Pancreas provides the documented high exocrine glandular reference; the listed adipose, adrenal, appendix, bone marrow, breast, bronchus, caudate, and cerebellum cell populations are reported as not detected (HPA tissue IHC). Interpret controls at the named cell level, since a tissue label alone does not describe every cell in its section. |
| Secretion and topology | UniProt describes a signal peptide at residues 1–15, a mature chain at 16–511, secretion, and no transmembrane segment (UniProt P04746). HPA observes cytoplasmic staining in pancreatic exocrine cells and cautions that secreted protein and RNA can occupy different tissue locations (HPA tissue IHC); extracellular colour therefore needs morphological and control review. |
| Antibody specificity and validation | HPA rates the tissue IHC profile Enhanced and records an IHC Enhanced result for CAB045960, while cautioning that the tissue profile targets proteins from more than one gene (HPA tissue IHC; HPA antibodies). Agreement with the reference pattern supports interpretation of the staining pattern but does not by itself isolate AMY2A from related targets. |
| IF/ICC localisation | HPA reports Golgi apparatus localisation as approved and cytosol as uncertain in ICC-IF, with a warning that the antibodies target proteins from multiple genes (HPA subcellular ICC-IF). That observation can inform an IF question, but it does not replace the pancreatic exocrine cytoplasmic reference used to score paraffin IHC (HPA tissue IHC). |
| Molecular annotations and assay limits | UniProt lists 2 isoforms and one glycosylation site at residue 476 (UniProt P04746). The supplied sources do not establish how either affects paraffin IHC detection, and they provide no target-specific fixation sensitivity. Keep retrieval and dilution choices tied to the antibody's own validated IHC conditions (general IHC practice). |
| Situation | Likely cause | Next action |
|---|---|---|
| Pancreatic exocrine cells are visible but unstained. | The expected positive population is missing (HPA tissue IHC); a failed staining or detection step is possible (general IHC practice). | Verify the positive-control section, reagent sequence, antibody dilution, retrieval conditions, and detection controls before interpreting the sample as negative (general IHC practice). |
| Most of the section develops diffuse chromogen. | Diffuse colour obscures HPA's selective exocrine cytoplasmic pattern (HPA tissue IHC). Nonspecific background or endogenous detection activity is possible (general IHC practice). | Compare a no-primary control, review blocking and washes, and assess the detection system's endogenous-activity control (general IHC practice). Score only cells whose signal remains distinguishable from background. |
| A strong nuclear or sharply membrane-bound pattern dominates. | The compartment differs from the observed cytoplasmic IHC pattern (HPA tissue IHC) and is unsupported by the non-transmembrane topology (UniProt P04746). | Check section morphology and negative controls, then review antibody specificity and staining conditions before assigning a biological localisation (general IHC practice). |
| Cells outside the expected exocrine population stain strongly. | This departs from HPA's selective pancreatic exocrine pattern (HPA tissue IHC). Cross-reactivity or endogenous detection activity may contribute (general IHC practice). | Identify the stained cell type on the counterstain, compare it with HPA's named cell-level observations, and use a no-primary control to assess detection background (HPA tissue IHC; general IHC practice). |
| ICC-IF suggests Golgi or cytosolic signal, while paraffin IHC shows a broader cytoplasmic pattern. | The supplied HPA records describe different assays: Golgi is approved and cytosol uncertain for ICC-IF, whereas pancreatic exocrine cytoplasm is the tissue IHC reference (HPA subcellular ICC-IF; HPA tissue IHC). | Judge the paraffin section against the tissue IHC reference and its controls; interpret ICC-IF localisation within its own assay, retaining HPA's multi-gene targeting caveat (HPA tissue IHC; HPA subcellular ICC-IF). |
Experiment evidence
IHC & IF images showing AMY2A staining
A06771 · IHCImmunohistochemistry of paraffin-embedded human liver injury using AMY2A antibody at dilution of 1:100 (x40 lens).
A06771 · IHCImmunohistochemistry of paraffin-embedded human gastric cancer using AMY2A antibody at dilution of 1:100 (x40 lens).
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000243480-AMY2A/tissue/cerebral+cortex#imid_14688580
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000243480-AMY2A/tissue/colon#imid_14681786
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000243480-AMY2A/tissue/liver#imid_14681795
HPA · PancreasHuman Protein Atlas IHC, Pancreas. Source: https://www.proteinatlas.org/ENSG00000243480-AMY2A/tissue/pancreas#imid_14682314
HPA · ICC-IF EFO-21Human Protein Atlas immunofluorescence, EFO-21, antibody HPA045394; green = AMY2A, blue = nucleus, red = microtubules.
HPA · ICC-IF EFO-21Human Protein Atlas immunofluorescence, EFO-21, antibody HPA045394; green = AMY2A, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for AMY2A IHC & IF
🧪Run pancreas first: exocrine glandular cells should stain (HPA: High in pancreatic exocrine glandular cells). Use adipose tissue as a negative tissue, focusing on adipocytes (HPA: Not detected in adipocytes); non-exocrine cells on the pancreas slide should lack specific staining and serve as an internal background reference.
Positive control tissue: Pancreas (Exocrine glandular cells, HPA High)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show AMY2A in EFO-21, SiHa, U2OS, with annotated localisation: Golgi apparatus (approved), Cytosol (uncertain) (HPA subcellular).
Technical controls: Include a no-primary, secondary-only control; an isotype control matched to the primary antibody’s host species and immunoglobulin class or subclass; and AMY2A knockout material or a cognate peptide block if available. In pancreas, check endogenous peroxidase before chromogenic detection and tissue autofluorescence if evaluating IF.
⚠️Feasibility: A target-specific fixation window and retrieval dependency are unreported in the supplied evidence; the selected A06771 paraffin-section caption does not report a fixative (selected SKU caption: paraffin-embedded section; fixative unreported). Frozen sections and IF are not established as easier for this target; the HPA ICC-IF localization carries a multiple-gene antibody caveat (HPA subcellular). Pancreatic autolysis can obscure morphology, and extracellular staining needs care when assigning signal to cells (UniProt P04746: secreted, extracellular space).
HPA tissue IHC evidence for AMY2A
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Enhanced — High consistency between antibody staining and RNA expression data. Caution, targets protein from more than one gene. Secreted protein, tissue location of RNA and protein is expected to differ.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Pancreas | Exocrine glandular cells | High | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Adrenal gland | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Appendix | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | Not detected | Protein (IHC) | HPA → |
| Breast | Adipocytes | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced AMY2A IHC Tips
Use pancreatic exocrine staining, compartment pattern, and matched controls to troubleshoot AMY2A chromogenic IHC in paraffin sections.
How should I retrieve AMY2A in paraffin sections when staining is weak?
Start with citrate pH 6.0 HIER at 95–98 °C for 20 min (page retrieval setting). Run a pancreatic exocrine control alongside the test section, because selective cytoplasmic staining in those cells provides a useful reference pattern (HPA tissue IHC). If staining remains weak, compare a slightly shorter or longer heating interval on adjacent sections while holding antibody and detection conditions constant (standard IHC practice). Assess tissue preservation and background before increasing retrieval intensity, and do not treat the liver injury caption’s 1:100 antibody dilution as evidence for a retrieval method (A06771 caption; standard IHC practice).
Could fixation explain weak or uneven AMY2A staining?
Target-specific fixation sensitivity is unknown: the selected paraffin-section caption does not report a fixative (A06771 caption). Record each specimen’s fixative and fixation duration, then compare sections processed together using citrate pH 6.0 HIER for 20 min (page retrieval setting; standard IHC practice). Include a pancreatic exocrine control in each comparison, since its selective cytoplasmic signal provides a tissue reference (HPA tissue IHC). If staining varies with processing, describe that association as an observation and check morphology, retrieval, and detection before attributing the difference specifically to fixation (standard IHC practice).
Where should convincing AMY2A staining appear in tissue?
Look first for cytoplasmic staining in pancreatic exocrine glandular cells, the selective tissue pattern reported for AMY2A (HPA tissue IHC). AMY2A has a signal peptide at residues 1–15 and is annotated as secreted into extracellular space, so extracellular signal can also warrant evaluation in context (UniProt P04746 processing and subcellular annotation). Score cellular and extracellular staining separately rather than calling every stained deposit a positive cell (standard IHC practice). A predominantly nuclear pattern conflicts with the reported tissue pattern and secreted-protein annotation; investigate counterstain overlap, tissue damage, and detection background before interpreting it as AMY2A (HPA tissue IHC; UniProt P04746; standard IHC practice).
Can this stain distinguish AMY2A isoforms or prove gene-specific expression?
Do not assign a stain to isoform 1 or 2 without an antibody epitope mapped against both sequences (UniProt P04746 isoforms; standard IHC practice). The record lists a processed chain spanning residues 16–511 and one glycosylation site at residue 476, but supplies no antibody epitope (UniProt P04746 processing and glycosylation; supplied antibody evidence). The HPA tissue assessment explicitly cautions that its antibodies target proteins from more than one gene, limiting gene-specific inference from that staining (HPA tissue IHC). Check the catalog antibody’s documented immunogen and cross-reactivity before making a specificity claim, and interpret morphology alongside appropriate controls (standard IHC practice).
How should I assess AMY2A in a multiplex IF experiment?
Pair AMY2A with a marker that identifies pancreatic exocrine glandular cells, the expected positive cell type in tissue (HPA tissue IHC). Choose a fluorophore and detection channel after checking unstained tissue autofluorescence, then include single-label controls to identify spectral spillover (standard IF practice). For intracellular staining, permeabilise sufficiently to expose the antibody’s epitope within secretory compartments; for an accessible extracellular epitope, compare without permeabilisation, since AMY2A is secreted and has no transmembrane segment (UniProt P04746 topology and subcellular annotation; standard IF practice). Treat HPA Golgi localisation cautiously because its subcellular antibodies target proteins from multiple genes (HPA subcellular).
How can I reduce diffuse brown signal without losing AMY2A staining?
Compare test sections with a no-primary control and a pancreatic exocrine positive control before changing the antibody concentration (standard IHC practice; HPA tissue IHC). Check peroxidase blocking, protein blocking, washes, and DAB development time, since each can affect chromogenic background independently of AMY2A (standard IHC practice). The selected liver injury image used antibody A06771 at 1:100 on paraffin sections, but its caption gives no fixation or detection details (A06771 caption). Because AMY2A is secreted, evaluate diffuse extracellular staining against tissue structure and controls before classifying it as nonspecific background or cell-associated expression (UniProt P04746 subcellular annotation; standard IHC practice).
What should I score when AMY2A staining varies across a section? ⚠ ANSWER MARKED FOR VERIFICATION
Define the scoring compartment before analysis: count pancreatic exocrine glandular cells separately from extracellular staining or deposits (HPA tissue IHC; UniProt P04746 subcellular annotation). For cellular signal, report the percentage of positive exocrine cells and an H-score using intensity grades 0–3, with the scoring rules applied consistently across sections (standard IHC practice). For extracellular signal, report stained area or optical density per mm² of intact tissue, using the same threshold and imaging settings (standard image-analysis practice). Normalise cellular results to evaluable exocrine cells and extracellular results to intact tissue area, while excluding folds, edges, and necrosis by predefined criteria (standard IHC practice).
When is an unexpected positive AMY2A stain credible?
Give greatest weight to a reproducible cytoplasmic signal in pancreatic exocrine glandular cells, which matches the reported selective tissue pattern (HPA tissue IHC). Examine unexpected liver injury staining against a pancreatic control and a no-primary control; the A06771 caption documents paraffin-section staining at 1:100 but does not establish its cellular source (A06771 caption; standard IHC practice). Flag staining confined to section edges, necrotic areas, or an unexpected nuclear compartment for review before calling it positive (standard IHC practice; UniProt P04746 subcellular annotation). Check endogenous peroxidase contribution and distinguish extracellular deposits from stained cells, particularly for a secreted protein (standard IHC practice; UniProt P04746 subcellular annotation).
Boster reagents
Best AMY2A / Pancreatic alpha-amylase IHC Antibodies
A06771 has real IHC data from paraffin-embedded human liver injury and gastric cancer samples (catalog IHC image captions). Human, Mouse and Rat are listed as reactive species (catalog: reactivity).
Real IHC data
Anti-Pancreatic alpha-amylase AMY2A Antibody
Cat # A06771
A06771 renders with an IHC figure from paraffin-embedded human liver injury at 1:100 (catalog IHC image caption). Its catalog also includes an IHC image from paraffin-embedded human gastric cancer at 1:100 (catalog IHC image caption).
Which to pick: For tissue IHC, choose A06771 for paraffin sections; its pictured human sample uses 1:100, within the listed 1:50–1:200 IHC range (catalog IHC image caption; datasheet: IHC dilution). No SKU in this payload has listed IF/ICC validation or IF images, so there is no supported IF/ICC pick (catalog: applications and IF image alts). For cross-species work, A06771 lists Human, Mouse and Rat reactivity, though its IHC images show human samples only; the paraffin captions do not report the fixative (catalog: reactivity and IHC image captions).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry P04746 (AMYP_HUMAN, Pancreatic alpha-amylase).
- Human Protein Atlas. AMY2A tissue IHC expression (reliability: Enhanced).
- Human Protein Atlas. AMY2A subcellular location (ICC-IF): Localized to the Golgi apparatus and cytosol. Caution: Based on antibodies targeting proteins from multiple genes..
- Human Protein Atlas. AMY2A antibody validation summary (4 antibodies).
- Brain alpha-amylase: a novel energy regulator important in Alzheimer disease?. Brain pathology (Zurich, Switzerland) 2018 — PMC8028266.
- PubMed PMID:6610603 — UniProt-cited evidence.
- PubMed PMID:2450054 — UniProt-cited evidence.
- PubMed PMID:6336237 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for AMY2A (Pancreatic alpha-amylase). Expected localisation Cytoplasmic staining observed in pancreatic exocrine cells (HPA tissue IHC). Antigen retrieval: Citrate pH 6.0 HIER, 95–98 °C, 20 min (rule: cytoplasmic / membrane antigen). Validated IHC antibody: A06771 at 1:50-1:200 (the product's own IHC validation image is shown). Controls (HPA): positive Pancreas (Exocrine glandular cells); negative Adipose tissue. IHC workflow; specimen preparation unspecified. Protocol steps: 1. Sample: Paraffin-embedded human liver injury tissue; fixative not specified (datasheet A06771); 2. Fixation: Image fixative and duration unreported (datasheet A06771); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat-induced epitope retrieval in citrate buffer, pH 6.0 , 20 min at 95–98 °C…; 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% normal serum of the secondary host, 30 min , room temperature (standard); 8. Primary antibody: Rabbit anti-AMY2A, 1:50-1:200 (datasheet A06771); 9. Primary incubation: Overnight at 4 °C (standard). Watch for: Fixation: Matched tissue-IHC evidence does not establish the fixation claim. Validate the specimen-specific method before use. (selected-SKU IHC image A06771); Caveat: Secreted protein may extend beyond its producing cells (UniProt); Isoform / epitope: 2 isoforms; signal peptide is cleaved; epitope unknown (UniProt); Regulation: Regulation not annotated (UniProt). Evidence: UniProt P04746, HPA tissue IHC · Enhanced, HPA ICC-IF · Golgi apparatus and cytosol. Caution: Based on antibodies targeting…, Datasheet A06771, PMC8028266. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/AMY2A/immunohistochemistry-ihc-guide.